DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 04/17/26
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)GlobeNewsWire • 04/03/26
Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.Investors Business Daily • 04/01/26
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome TranscriptSeeking Alpha • 03/26/26
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)GlobeNewsWire • 03/25/26
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum TranscriptSeeking Alpha • 03/21/26
Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/06/26
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in FocusZacks Investment Research • 02/27/26
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsGlobeNewsWire • 02/26/26
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™GlobeNewsWire • 02/05/26
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™GlobeNewsWire • 02/02/26
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™GlobeNewsWire • 01/29/26
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)GlobeNewsWire • 12/30/25